Senores Pharmaceuticals Ltd
Thu 13/03/2025,15:57:9 | NSE : SENORES
Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.
Market Data
Essential tool: analyze, trade, manage, decide.
Open
₹ 578.95
Previous Close
₹ 576.15
Volume
470206
Mkt Cap ( Rs. Cr)
₹2609.86
High
₹ 587.95
Low
₹ 556.60
52 Week High
₹ 644.80
52 Week Low
₹ 435.25
Book Value Per Share
₹ 66.07
Dividend Yield
0.00
Face Value
₹ 10.00
What’s Your Call?
Collective community sentiment on Senores Pharmaceuticals Ltd
Your Vote -
Buy
33.33%
Hold
33.33%
Sell
33.33%
33.33%
3 users have voted
Market Depth
How many stocks are available to buy or sell and at what prices.
Buy Order Quantity
0%
Sell Order Quantity
100%
Bid Price
Qty
0.00
0
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
0
Bid Price
Qty
566.70
3698
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
3698
Option Chain
Analyzes market sentiment, predicts Senores Pharmaceuticals Ltd' movement.
NO_RECORD_FOUND
News
Media spotlight triggers stock stock attention, sentiment.
-
Senores Pharmaceutic - Update-Acquisition/Scheme/Sale/Disposal-XBRL
-
Senores Pharmaceutic - Additional Disclosure In Respect Of Our Intimation Dated March 11, 2025, Pursuant To Regulation 30 Of
-
Senores Pharmaceutic - General Updates
-
Senores Pharmaceutic - Acquisition-XBRL
-
Senores Pharmaceutic - General Updates
-
Senores Pharmaceutic - Announcement under Regulation 30 (LODR)-Acquisition
-
Senores Pharmaceutic - Press Release
-
Senores Pharmaceutic - Announcement under Regulation 30 (LODR)-Press Release / Media Release
-
Senores Pharmaceuticals to acquire 14 ANDAs from Dr Reddy's Laboratories
-
Senores Pharmaceutic - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
-
Senores Pharmaceutic - Analysts/Institutional Investor Meet/Con. Call Updates
-
Senores Pharmaceutic - Press Release
-
Senores Pharmaceutic - General Updates
-
Senores Pharmaceutic - Acquisition-XBRL
-
Senores Pharmaceutic - Announcement under Regulation 30 (LODR)-Press Release / Media Release
-
Senores Pharmaceutic - Announcement Regarding Inauguration Of Second Active Pharmaceutical Ingredient ('API') Manufacturing F
-
Senores Pharmaceutic - Announcement under Regulation 30 (LODR)-Acquisition
-
Senores Pharmaceutic - Updates
-
Senores Pharmaceutic - Press Release
-
Senores Pharmaceutic - Announcement under Regulation 30 (LODR)-Press Release / Media Release
-
Senores Pharmaceutic - Updates
-
Senores Pharmaceutic - Intimation For Change In The Domain Name And Generic E-Mail ID Of The Registrar And Share Transfer A
-
Senores Pharmaceutic - Analysts/Institutional Investor Meet/Con. Call Updates
-
Senores Pharmaceutic - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
-
Senores Pharmaceutic - Analysts/Institutional Investor Meet/Con. Call Updates
-
Senores Pharmaceutic - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
-
Senores Pharmaceutic - Copy of Newspaper Publication
-
Senores Pharmaceutic - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
-
Senores Pharmaceutic - Analysts/Institutional Investor Meet/Con. Call Updates
-
Senores Pharmaceutic - Integrated Filing (Financial)
-
Senores Pharmaceutic - Integrated Filing- Financial
-
Senores Pharmaceutic - Appointment of Secretarial Auditor
-
Senores Pharmaceutic - Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent
-
Senores Pharmaceutic - Change in Auditors
-
Senores Pharmaceutic - Monitoring Agency Report
-
Senores Pharmaceutic - Investor Presentation
-
Senores Pharmaceutic - Statement of deviation(s) or variation(s) under Reg. 32
-
Senores Pharmaceutic - Press Release
-
Senores Pharmaceutic - Financial Result Updates
-
Senores Pharmaceutic - Outcome of Board Meeting
-
Senores Pharmaceutic - Monitoring Agency Report for the quarter ended December 31, 2024
-
Senores Pharmaceutic Q3 net profit zooms 435.00% at Rs 1.07 cr
-
Senores Pharmaceutic - Investor Presentation
-
Senores Pharmaceutic - Statement Of Deviation/Variation, If Any For The Quarter Ended December 31, 2024.
-
Senores Pharmaceutic - Media Release For Q3 And 9MFY25
-
Senores Pharmaceutic - Results For Quarter And Nine Months Ended December 31, 2024
-
Senores Pharmaceutic - Board Meeting Outcome for Outcome Of Board Meeting Held On 23-01-2025.
-
Senores Pharmaceutic - Updates
-
Senores Pharmaceutic - Intimation Under Regulation 30(6) Of SEBI (LODR) Regulations, 2015.
-
Senores Pharmaceutic - Certificate under SEBI (Depositories and Participants) Regulations, 2018
-
Senores Pharmaceutic - Certificate under SEBI (Depositories and Participants) Regulations, 2018
-
Senores Pharmaceutic - Press Release
-
Senores Pharmaceutic - Announcement under Regulation 30 (LODR)-Press Release / Media Release
-
Senores Pharmaceutic - Intimation Under Regulation 30(5) Of The SEBI (LODR) Regulations, 2015.
-
Senores Pharmaceutic - Updates
-
Senores Pharmaceutic - Trading Window-XBRL
-
Senores Pharmaceutic - Trading Window
-
Senores Pharmaceutic has submitted to BSE the Shareholding Pattern for the Period Ended December 26, 2024
-
Senores Pharmaceuticals Ltd. debuts with 51.84% premium at Rs 593.70
-
Senores Pharmaceutic announces launch of initial public offering
-
Senores Pharmaceuticals acquires ANDA for Roflumilast
Key fundamentals
Evaluate the intrinsic value of Senores Pharmaceuticals Ltd stock
| Name | March-24 | March-23 | March-22 | ||
|---|---|---|---|---|---|
| Assets | 260.871 | 99.332 | 48.2313 | ||
| Liabilities | 260.871 | 99.332 | 48.2313 | ||
| Equity | 30.505 | 9.818 | 8.7422 | ||
| Gross Profit | -0.062 | -1.78 | 0.9342 | ||
| Net Profit | 0.814 | 1.199 | 0.293 | ||
| Cash From Operating Activities | -62.818 | -43.414 | -12.1977 | ||
| NPM(%) | 2.39 | 9.68 | 1.84 | ||
| Revenue | 34.006 | 12.382 | 15.8508 | ||
| Expenses | 34.068 | 14.162 | 14.9166 | ||
| ROE(%) | 0.26 | 0.39 | 0.09 |
Corporate Action
| XD-Date | Dividend-Amount | Dividend-% | Dividend Yield(%GE) | Price on that day |
|---|
Peers
Other companies within the same industry or sector that are comparable to Senores Pharmaceuticals Ltd
| Company | Price | Price (% change) | pe(x) | EV/EBITDA(x) | ROE(%) | ROCE(%) |
|---|---|---|---|---|---|---|
| Albert David Ltd | 808.20 | -1.14 | 11.41 | 322.34 | 1321.50 | 1.42 |
| Lotus Eye Hospital and Institute Ltd | 57.06 | -0.77 | 237.75 | 1174.57 | 14.01 | 0.88 |
| Vaishali Pharma Ltd | 12.12 | -5.90 | 606.00 | 605.42 | 2.31 | 0.00 |
| Astec Lifesciences Ltd | 653.90 | -5.55 | 0.00 | 1107.52 | -239.30 | 0.00 |
Company Info
Our Company was originally incorporated as "Senores Pharmaceuticals Private Limited" a private limited company under the Companies Act, 2013 through certificate of incorporation dated December 26, 2017, issued by the Registrar of Companies, Central Registration Centre.The name of the Company was thereafter changed to "Senores Pharmaceuticals Limited" upon conversion to a public limited company pursuant to a Board resolution dated August 1, 2023, a special resolution passed in the extraordinary general meeting of the Shareholders held on August 24, 2023 and the approval of the central government dated September 4, 2023, and consequently a fresh certificate of incorporation dated September 4, 2023, was issued by the RoC to reflect the change in name.Major Events and Milestones:2021- Incorporated a wholly owned subsidiary, Senores Pharmaceuticals Inc in the US.2021- Entered into a new segment of API with acquisition of Ratnagene Lifescience Private Limited.2022- Started the domestic business with a launch of the critical care injectables2023- Acquired majority stake in Havix., making it a Subsidiary of our Company- Consolidated our presence in emerging markets by acquiring shares in Ratnatris Pharmaceuticals Private Limited, making a Subsidiary of our Company.2024- Launched first CMO product in the US with Jubilant Cadista
Our Company was originally incorporated as "Senores Pharmaceuticals Private Limited" a private limited company under the Companies Act, 2013 through certificate of incorporation dated December 26, 2017, issued by the Registrar of Companies, Central Registration Centre.The name of the Company was thereafter changed to "Senores Pharmaceuticals Limited" upon conversion to a public limited company pursuant to a Board resolution dated August 1, 2023, a special resolution passed in the extraordinary general meeting of the Shareholders held on August 24, 2023 and the approval of the central government dated September 4, 2023, and consequently a fresh certificate of incorporation dated September 4, 2023, was issued by the RoC to reflect the change in name.Major Events and Milestones:2021- Incorporated a wholly owned subsidiary, Senores Pharmaceuticals Inc in the US.2021- Entered into a new segment of API with acquisition of Ratnagene Lifescience Private Limited.2022- Started the domestic business with a launch of the critical care injectables2023- Acquired majority stake in Havix., making it a Subsidiary of our Company- Consolidated our presence in emerging markets by acquiring shares in Ratnatris Pharmaceuticals Private Limited, making a Subsidiary of our Company.2024- Launched first CMO product in the US with Jubilant Cadista
Read More
Parent Organisation
Senores Pharmaceuticals Ltd.
Founded
26/12/2017
Managing Director
Mr.Swapnil Jatinbhai Shah
NSE Symbol
SENORESEQ
FAQ
The current price of Senores Pharmaceuticals Ltd is ₹ 566.70.
The 52-week high for Senores Pharmaceuticals Ltd is ₹ 587.95 and the 52-week low is ₹ 556.60.
The market capitalization of Senores Pharmaceuticals Ltd is currently ₹ 2609.86. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.
To buy Senores Pharmaceuticals Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.
To invest in Senores Pharmaceuticals Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Senores Pharmaceuticals Ltd shares.
The CEO of Senores Pharmaceuticals Ltd is Mr.Swapnil Jatinbhai Shah, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.
